Motif Bio plc

The US Food and Drug Administration wants to see another clinical trial of Motif Bio PLC ’s antibiotic iclaprim with a longer follow-up period to assess the potential for latent liver toxicity, the c

Motif Bio PLC has been dealt a serious blow from the US Food and Drug Administration which has told the cash-strapped UK biotech it needs to carry out an additional trial for iclaprim if it wants any

The under-pressure UK biotech, Motif Bio PLC , has presented more clinical data on its lead Gram-positive targeted investigational antibacterial, iclaprim, as it prepares for a meeting with US regula

The US FDA's Center for Drug Evaluation and Research (CDER) approved its third novel product of the year with a Feb. 13 blessing for Novartis AG 's Egaten (triclabendazole), which also resulted in